JPWO2020172559A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020172559A5 JPWO2020172559A5 JP2021548688A JP2021548688A JPWO2020172559A5 JP WO2020172559 A5 JPWO2020172559 A5 JP WO2020172559A5 JP 2021548688 A JP2021548688 A JP 2021548688A JP 2021548688 A JP2021548688 A JP 2021548688A JP WO2020172559 A5 JPWO2020172559 A5 JP WO2020172559A5
- Authority
- JP
- Japan
- Prior art keywords
- modified
- modified oligonucleotide
- sugar moiety
- oligomeric compound
- nucleobase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962809492P | 2019-02-22 | 2019-02-22 | |
| US62/809,492 | 2019-02-22 | ||
| PCT/US2020/019272 WO2020172559A1 (en) | 2019-02-22 | 2020-02-21 | Compounds and methods for reducing atxn3 expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022520986A JP2022520986A (ja) | 2022-04-04 |
| JPWO2020172559A5 true JPWO2020172559A5 (https=) | 2023-03-02 |
| JP2022520986A5 JP2022520986A5 (https=) | 2023-03-02 |
Family
ID=72143504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548688A Pending JP2022520986A (ja) | 2019-02-22 | 2020-02-21 | Ａｔｘｎ３発現を減少させるための化合物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220195431A1 (https=) |
| EP (1) | EP3927827A4 (https=) |
| JP (1) | JP2022520986A (https=) |
| WO (1) | WO2020172559A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190104A1 (ar) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن atxn3 |
| SG11202010215TA (en) | 2018-05-09 | 2020-11-27 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing atxn3 expression |
| EP3980539A1 (en) * | 2019-06-06 | 2022-04-13 | F. Hoffmann-La Roche AG | Antisense oligonucleotides targeting atxn3 |
| JP7776420B2 (ja) | 2020-05-12 | 2025-11-26 | 田辺三菱製薬株式会社 | Ａｔａｘｉｎ ３発現を調節するための化合物、方法及び医薬組成物 |
| TW202237842A (zh) | 2020-12-03 | 2022-10-01 | 瑞士商赫孚孟拉羅股份公司 | 靶向ａｔｘｎ３之反義寡核苷酸 |
| WO2022117747A2 (en) | 2020-12-03 | 2022-06-09 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting atxn3 |
| US20240336915A1 (en) * | 2021-01-22 | 2024-10-10 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing dux4 expression |
| WO2025252669A1 (en) | 2024-06-03 | 2025-12-11 | Evotec International Gmbh | Modified oligonucleotides for reducing atxn3 expression |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001250572A1 (en) * | 2000-04-07 | 2001-10-23 | Epigenomics Ag | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
| US8178503B2 (en) * | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
| JP2015511821A (ja) * | 2012-03-12 | 2015-04-23 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ | Ａｔｘｎ３発現の調節のための組成物および方法 |
| US10533175B2 (en) * | 2015-09-25 | 2020-01-14 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating Ataxin 3 expression |
| WO2018002886A1 (en) * | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia 3 (sca3) and other related disorders |
| SG11202010215TA (en) * | 2018-05-09 | 2020-11-27 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing atxn3 expression |
-
2020
- 2020-02-21 US US17/432,237 patent/US20220195431A1/en active Pending
- 2020-02-21 WO PCT/US2020/019272 patent/WO2020172559A1/en not_active Ceased
- 2020-02-21 EP EP20758529.0A patent/EP3927827A4/en active Pending
- 2020-02-21 JP JP2021548688A patent/JP2022520986A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541404A (ja) | ＤＵＸ４の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用方法 | |
| JP2021522800A5 (https=) | ||
| JP2021530204A5 (https=) | ||
| JPWO2022270585A5 (https=) | ||
| JP2019525918A5 (https=) | ||
| JPWO2020132227A5 (https=) | ||
| KR20210127917A (ko) | 트리루프를 함유하는 이중-가닥의 핵산 억제제 분자 | |
| TW201919654A (zh) | 用於抑制α-ENaC表現之RNAi試劑及使用方法 | |
| JPWO2020006267A5 (https=) | ||
| TW202426645A (zh) | 用於抑制DM1蛋白質激酶(DMPK)表現之RNAi藥劑、其組合物及使用方法 | |
| JPWO2019022196A1 (ja) | 一本鎖オリゴヌクレオチド | |
| TW202043470A (zh) | 用於抑制HIF-2α(EPAS1)表現之RNAi藥劑、其組合物及使用方法 | |
| JPWO2020172559A5 (https=) | ||
| US20240254488A1 (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
| JPWO2020160163A5 (https=) | ||
| CN114555188A (zh) | 治疗apoc3相关疾病和病症的方法 | |
| US12503696B2 (en) | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of use | |
| US20200318113A1 (en) | Polynucleotide conjugates and uses thereof | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| JP2021517909A (ja) | 胆管減少症関連状態を治療するための方法及び組成物 | |
| JPWO2022159712A5 (https=) | ||
| JPWO2022026589A5 (https=) | ||
| JPWO2022218941A5 (https=) | ||
| JPWO2020055917A5 (https=) | ||
| JPWO2020190740A5 (https=) |